Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

BELLUS Health doses first patient in Phase 2b chronic cough trial

BELLUS Health (NASDAQ:BLU; TSX:BLU) dosed the first patient in its Phase 2b study evaluating BLU-5937 for the treatment of refractory chronic cough. The study, called SOOTHE, will evaluate three doses of BLU-5937 in...

December 8, 2020

Developments

electroCore reports positive topline results from migraine prevention study

electroCore (NASDAQ:ECOR) reported positive topline results from its PREMIUM II study evaluating gammaCore, a non-invasive vagus nerve stimulation (nVNS) device, for the prevention of migraines. The study was designed...

December 8, 2020

Markets

HCW starts Prothena at buy; PT $22

H.C. Wainwright launched coverage of Prothena (NASDAQ:PRTA) with a “buy” rating and price target of $22. The stock closed at $11.53 on Dec 4. Prothena is focused on protein-opathies affecting the central nervous system...

December 7, 2020

Markets

HCW starts BiomX at buy; PT $20

H.C. Wainwright initiated coverage of BiomX (NYSE American:PHGE) with a “buy” rating and $20 price target. The stock closed at $5.90 on Dec 4. “BiomX is one of the leaders in the development of bacteriophage (phage)...

December 7, 2020

Developments

Precision BioSciences reports positive interim data from Phase 1/2a lymphoma, leukemia study

Precision BioSciences (NASDAQ:DTIL) reported positive interim results from its Phase 1/2a study evaluating PBCAR0191, an allogeneic chimeric antigen receptor (CAR-T) cell therapy, for the treatment of...

December 4, 2020

Markets

HCW starts Liquidia Technologies at buy; PT $6

H.C. Wainwright initiated coverage of Liquidia Technologies (NASDAQ:LQDA) with a “buy” rating and price target of $6. The stock closed at $2.92 on Dec. 3. Liquidia is focused on applying its particle engineering PRINT...

December 4, 2020

Executive Moves

Benjamin Bowen joins Roth’s healthcare investment banking team

Benjamin Bowen Benjamin Bowen, Ph.D., has joined Roth Capital Partners as managing director, healthcare investment banking. Prior to joining Roth, Dr. Bowen most recently was managing director in the investment banking...

December 4, 2020

Developments

Taysha gets FDA rare pediatric and orphan drug designations for epilepsy

Taysha Gene Therapies’ (NASDAQ:TSHA) TSHA-103 received FDA rare pediatric and orphan drug designations for the treatment of SLC6A1-related epilepsy. SLC6A1-related epilepsy is caused by the loss of function of one copy...

December 3, 2020

Markets

Stifel starts Syndax Pharmaceuticals at buy; PT $32

Stifel launched coverage of Syndax Pharmaceuticals (NASDAQ:SNDX) with a “buy” rating and price target of $32. The stock closed at $22.79 on Dec. 2. Analyst Konstantinos Aprilakis, M.D., writes that SNDX-5613, the...

December 3, 2020

Markets

Stifel starts Sutro Biopharma at buy; PT $25

Stifel initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a “buy” rating and $25 price target. The stock closed at $16.35 on Dec. 2. Sutro is developing XpressCF, a cell-free protein-synthesis platform that...

December 3, 2020

Developments

Protagonist Therapeutics gets FDA fast track designation for polycythemia vera

Protagonist Therapeutics’ (NASDAQ:PTGX) PTG-300 received FDA fast track designation for the treatment of polycythemia vera, a rare disease characterized by the excessive production of red blood cells. PTG-300 is an...

December 2, 2020

Developments

Cara Therapeutics completes enrollment in Phase 2 pruritis trial

Cara Therapeutics (NASDAQ:CARA) completed enrollment in its Phase 2 KARE trial evaluating KORSUVA for the treatment of moderate-to-severe pruritus, or itchy skin, in atopic dermatitis patients. The trial enrolled 400...

December 2, 2020

Subscribe